Abstract
IL-15 has been actively investigated for its potential in tumor immunotherapy. To enhance the anti-tumor activity of IL-15, the novel PFC-1 construct was designed, which comprises the following 3 parts: (1) IL-15Rα fused with IL-15 to enhance IL-15 activity, (2) an Fc fragment to increase protein half-life, and (3) an integrin-targeting RGD peptide to enhance tumor targeting. PFC-1 showed tumor cell targeting without compromising IL-15 activity. PFC-1 also had potent anti-tumor activities in xenograft models, suggesting the potential application of this multi-functional fusion protein in tumor therapy.
Disclose of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
We are grateful to Dr. Mengfeng Li and Dr. Jiang Li at the Sun Yat-Sen University School of Medicine, and Dr. Wei Xie at the Sun Yat-Sen University School of Life Sciences for their technical support and valuable discussions.
Supplemental Material
Supplemental data for this article can be accessed on the publisher's website.
Funding
The financial support for this work was from the Introduced Innovative R&D Team Leadership of Guangdong Province (PR China) (2011Y038).